

Berga Backe 2, Box 712, 182 17 Danderyd, Sweden

Patient Organisation Agreement

This Patient Organisation Agreement has been drawn up and entered into as of 12 January 2022 by and between

CSL Behring AB, Box 712, 182 17 Danderyd, SWEDEN, Reg. no. 556530-1974

and

Alpha 1 Denmark Sangfuglestien 5, st. 2400 København NV formanden@alfa-1.dk / heinrich.andreasen@alfa-1.dk

1. Background

Alpha-1-antitrypsin deficiency (ZZ) can cause lung disease and even rarer liver disease in adults and in some children also liver disease from birth.

The purpose of Alfa-1 Denmark is to optimize living conditions for people with Alpha-1 antitrypsin deficiency and create a forum for Alfa-1 patients and their relatives for mutual support, exchange of experience and knowledge acquisition. The aim is also to gain public understanding, acceptance and support to meet the needs of Alpha-1 patients and promote international cooperation on Alpha-1 antitrypsin deficiency.

CSL Behring operate in this field by improving treatment for patients living with alpha-1-antitrypsin deficiency (ZZ).

There is a common interest in improving alpha-1-antitrypsin treatment and care and to drive advocacy for improved patient access to treatment and care.

2. Collaboration project

To support Alpha-I patients around Denmark and the Nordic countries CSL Behring will support Alpha I Denmark with the recording of podcast-episodes about Alpha-I-antitrypsin deficiency with the aim to spread awareness about the disease and share patient experiences.

The support will be given as an unrestricted grant for Alpha 1 Denmark to produce up to five Podcast-episodes. Alpha-1 Denmark estimates the cost per episode to 51 000 SEK (See attachment)

The recorded podcast episodes will be published and distributed via Alpha 1 Denmarks website with the purpose of sharing the content with both patients, Health Care Professionals and others with interest in the field.

3. Finances

3.1 CSL Behring AB has undertaken to finance the producing of up to five podcastepisodes with 51 000 SEK per episode. Payment shall be made against separate invoice after the recording of each episode. The invoice shall be sent to <u>DanderydPayables@cslbehring.com</u>

State Therese Feinberg as reference on the invoice.

4. Transparency

- 4.1 Both Parties consent to the contents of this Agreement being shared with a third party.
- 4.2 Both parties consent to this agreement or a summary thereof being published on the company website and reported to ENLI in accordance with § 3 of the Patient



Berga Backe 2, Box 712, 182 17 Danderyd, Sweden

Organizations Code regulated by the Ethical Committee for the Pharmaceutical Industry, ENLI.

5. Consultation, evaluation

- 5.1 Alpha 1 Denmark has appointed Formand Claus Astradsson and Heinrich Andreasen as their contact persons in matters concerning this Agreement.
- 5.2 CSL Behring AB has appointed Pia Naested as their contact person in matters concerning this Agreement.

6. Agreement period and early termination

- 6.1 This Agreement is valid from 01/01/2022 until 31/12/2022.
- 6.2 If either party fails to fulfil their obligations pursuant to this Agreement and adjustments have not been made within thirty (30) days of the party being requested in writing to do so, the other party will be entitled to terminate the Agreement immediately.

7. Ethical rules and law

- 7.1 Ethical rules and national law apply to this agreement. Alpha 1 Denmark warrants that it will only use the funds received in accordance with national law and the Pharmaceutical Industry's Code of Ethics.
- 7.2 Alpha 1 Denmark may not refer to or make any representation relating to CSL Behring or its products or the co-operation under this agreement without CSL Behring's prior written approval. Alpha 1 Denmark shall submit all proposed materials mentioning CSL Behring, or referring to CSL Behring's products, or the co-operation under this agreement, to CSL Behring for written approval prior to publication or use.

8. Disputes

If a dispute should arise in conjunction with this Agreement, the Parties shall primarily attempt to resolve it through negotiation. In the event that the Parties are unable to reach an accord within thirty (30) days of the initial request for negotiation, the dispute shall be resolved in a Swedish Court.

9. E-signature

The Agreement may be executed by means of wet ink signatures or by using electronic signatures. If the Agreement is signed using electronic signatures, in making proof of this Agreement, an electronic copy of the Agreement will suffice. The Parties undertake not to dispute the validity of the Agreement based on the signatures being electronic.



Berga Backe 2, Box 712, 182 17 Danderyd, Sweden

This Agreement has been drawn up and signed in two (2) identical originals, of which each party has received an original.

Stockholm 210112

Place and Date:

CSL Behring AB:

DocuSigned by:

Petter Olbe

Name and title:

Petter Olbe

Marketing Manager, Nordic Region

220112

Place and Date:

CSL Behring AB:

DocuSigned by:

Name and title: Martin Tenlen

General Manager, Nordic Region

19-01-2020

Place and Date:

Alpha 1 Denmark:

-DocuSigned by:

Claus Astradsson

Name and title: Claus Astradsson

Formand

220127

Place and Date:

Alpha 1 Denmark:

-DocuSigned by:

Andreasen, Heinrich

Name and title:

Heinrich Andreasen